ArticleJournal of cardiovascular translational research2012
Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively.
Article in Journal of cardiovascular translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Combined heart and liver transplantation for homozygous familial hypercholesterolaemia: 35-year post-operative outcomes.Global cardiology science & practice · 2026Article
- Liver transplantation for homozygous familial hypercholesterolaemia.Current opinion in lipidology · 2025Review
- International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.Nature reviews. Cardiology · 2023Review
- 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.European heart journal · 2023Article
- Case Report: Liver Transplantation in Homozygous Familial Hypercholesterolemia (HoFH)-Long-Term Follow-Up of a Patient and Literature Review.Frontiers in pediatrics · 2020Article
- Article
- Combined heart-liver transplantation: Indications, outcomes and current experience.Transplantation reviews (Orlando, Fla.) · 2016Review
- Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management.Pediatric transplantation · 2016Review
- Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.Current atherosclerosis reports · 2016Review
- Current Treatment of Familial Hypercholesterolaemia.European cardiology · 2014Review
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.European heart journal · 2014Article
- Familial hypercholesterolemia: developments in diagnosis and treatment.Deutsches Arzteblatt international · 2014Review
- The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.Global cardiology science & practice · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We review the lessons from a case of combined heart and liver transplantation (CHLT) 20 years post-operatively from the molecular to clinical levels. CHLT replaces cardiac function and provides a new source of Low density lipoprotein-receptors (LDL-R) known to be deficient in Familial Hypercholesterolaemia. Little is known of the long-term outcomes of this strategy. We review the lessons from a case of CHLT 20 years post-operatively, which illustrate the successful transition from the molecular understanding of the pathophysiology to the clinical therapy. Most importantly, there is evidence that transplantation of multiple organs from a single donor promotes operational tolerance, especially in the case of the liver. This lady presented in severe heart failure with advanced atherosclerotic disease resulting in coronary artery and aortic valve stenosis. The serum LDL-C concentration of 13 mmol/L was refractory to conventional therapy. Genetic analysis showed a large deletion on one allele of the LDL-R, and a mutant allele that produced a receptor which was delayed in its transport to the cell membrane and had 10% of normal receptor activity. The patient had a normalised lipid-profile directly after CHLT (2.1 mmol/L), and this has remained stable since the time of operation. Apart from a minor episode of cardiac rejection at 3 weeks post-CHLT, the patient has had excellent heart and liver function throughout. This patient has not experienced any signs of rejection, despite only low-dose immunosuppression. We review what we have learnt from this case at the molecular and clinical levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.